386 related articles for article (PubMed ID: 34488749)
21. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States.
Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn AM; Lowry S; Feldman S; Wu JJ; Armstrong AW
J Dermatolog Treat; 2022 Mar; 33(2):740-748. PubMed ID: 32602762
[TBL] [Abstract][Full Text] [Related]
23. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
[TBL] [Abstract][Full Text] [Related]
24. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
25. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
Wu JJ; Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn A; Lowry S; Feldman SR; Armstrong A
J Dermatolog Treat; 2021 Nov; 32(7):693-700. PubMed ID: 32233828
[TBL] [Abstract][Full Text] [Related]
26. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy.
Spandonaro F; Ayala F; Berardesca E; Chimenti S; Girolomoni G; Martini P; Peserico A; Polistena B; Puglisi Guerra A; Vena GA; Altomare G; Calzavara Pinton P
BioDrugs; 2014 Jun; 28(3):285-95. PubMed ID: 24567261
[TBL] [Abstract][Full Text] [Related]
27. Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods.
Lasalvia P; Gil-Rojas Y; Papadimitropoulos E; Burge R; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):511-517. PubMed ID: 36927221
[TBL] [Abstract][Full Text] [Related]
28. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
Feldman SR; Wu JJ; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Med Econ; 2018 May; 21(5):537-541. PubMed ID: 29357713
[TBL] [Abstract][Full Text] [Related]
29. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
30. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
Puig L; Notario J; Jiménez-Morales A; Moreno-Ramírez D; López-Ferrer A; Gozalbo I; Prades M; Lizán L; Blanch C
J Dermatolog Treat; 2017 Nov; 28(7):623-630. PubMed ID: 28784002
[TBL] [Abstract][Full Text] [Related]
31. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
32. The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis.
Nyholm N; Danø A; Schnack H; Colombo GL
Clinicoecon Outcomes Res; 2023; 15():607-619. PubMed ID: 37533798
[TBL] [Abstract][Full Text] [Related]
33. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
[TBL] [Abstract][Full Text] [Related]
34. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
35. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective.
Zhang J; Xia Z; Guo W; Ren X; Liu F; Ratnaparkhi G; Pagada A; Subramanian S; Hu M; Chen W
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2681-2696. PubMed ID: 37741954
[TBL] [Abstract][Full Text] [Related]
37. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.
Igarashi A; Kuwabara H; Fahrbach K; Schenkel B
J Dermatolog Treat; 2013 Oct; 24(5):351-5. PubMed ID: 22632451
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]